Reported Earnings • Aug 26
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: kr.1.18m (down 69% from 2Q 2024). Net loss: kr.2.77m (loss widened 337% from 2Q 2024). Reported Earnings • May 25
First quarter 2025 earnings released First quarter 2025 results: Revenue: kr.244.0k (down 65% from 1Q 2024). Net loss: kr.2.93m (loss widened 13% from 1Q 2024). Duyuru • May 21
Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot Programme DanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms. Duyuru • Apr 11
DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025 DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025 Duyuru • Apr 05
DanCann Pharma A/S Provides Financial Guidance for 2025 DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million. Duyuru • Mar 28
DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025 DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025 Reported Earnings • Feb 20
Full year 2024 earnings released: kr.0.002 loss per share (vs kr.0.44 loss in FY 2023) Full year 2024 results: kr.0.002 loss per share (improved from kr.0.44 loss in FY 2023). Revenue: kr.7.76m (up 8.5% from FY 2023). Net loss: kr.7.93m (loss narrowed 87% from FY 2023). Duyuru • Feb 17
DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026 DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024.
Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives. Duyuru • Dec 11
DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of Directors DanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors. Reported Earnings • Nov 24
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr.1.86m (flat on 3Q 2023). Net loss: kr.2.86m (loss widened 3.7% from 3Q 2023). Duyuru • Oct 31
DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024 DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024 Reported Earnings • Aug 16
Second quarter 2024 earnings released: kr.0.004 loss per share (vs kr.0.05 loss in 2Q 2023) Second quarter 2024 results: kr.0.004 loss per share (improved from kr.0.05 loss in 2Q 2023). Revenue: kr.3.86m (up 38% from 2Q 2023). Net loss: kr.633.0k (loss narrowed 79% from 2Q 2023). Duyuru • Aug 14
DanCann Pharma A/S Revises Earnings Guidance for 2024 DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024. Duyuru • Aug 01
DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024 DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024 Duyuru • Jun 20
DanCann Pharma A/S Provides Revenue Guidance for the Year 2024 DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue. Reported Earnings • Jun 04
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr.702.0k (down 31% from 1Q 2023). Net loss: kr.2.60m (loss narrowed 26% from 1Q 2023). Duyuru • May 03
DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024 DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024 Duyuru • May 01
DanCann Pharma A/S, Annual General Meeting, May 30, 2024 DanCann Pharma A/S, Annual General Meeting, May 30, 2024. Duyuru • Apr 04
Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024 Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024 Reported Earnings • Mar 01
Full year 2023 earnings released: kr.0.13 loss per share (vs kr.0.25 loss in FY 2022) Full year 2023 results: kr.0.13 loss per share (improved from kr.0.25 loss in FY 2022). Revenue: kr.7.15m (flat on FY 2022). Net loss: kr.12.3m (loss narrowed 23% from FY 2022). Duyuru • Dec 20
Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025 Dancann Pharma A/S provided revenue guidance for the financial year 2025. For the year, the company targets a revenue growth exceeding 300%, and with that, attain the breakeven point by the year 2025. Reported Earnings • Dec 01
Third quarter 2023 earnings released: kr.0.033 loss per share (vs kr.0.096 loss in 3Q 2022) Third quarter 2023 results: kr.0.033 loss per share. Revenue: kr.1.86m (down 30% from 3Q 2022). Net loss: kr.2.75m (loss widened 1.3% from 3Q 2022). Reported Earnings • Sep 03
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr.2.80m (up 154% from 2Q 2022). Net loss: kr.3.02m (loss narrowed 35% from 2Q 2022). New Risk • Jul 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.18m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 57% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Revenue is less than US$1m (kr.6.6m revenue, or US$991k). Market cap is less than US$10m (kr.17.9m market cap, or US$2.69m). New Risk • Jun 08
New major risk - Revenue and earnings growth Earnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 57% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Revenue is less than US$1m (kr.6.6m revenue, or US$951k). Market cap is less than US$10m (kr.25.0m market cap, or US$3.61m). Duyuru • Jun 02
Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product Approval DanCann Pharma A/S announced the successful QC analysis of its pre-validation batches. The Company has confirmed that all batches have been tested in accordance with European (German and Danish) standards, meeting the required specifications and further advancing the approval process. As part of its commitment to ensuring the higher standards of quality and compliance, DanCann Pharma conducted comprehensive testing of its pre-validation batches. The testing process followed European (German and Danish) products. The results of the analysis have demonstrated that all pre-validation batches have successfully met the rigorous specifications set by European (German and Danish) standards. This achievement underscores DanCann Pharma's unwavering dedication to producing safe and effective therapeutic cannabinoids in line with the higher regulatory and industry requirements. Duyuru • May 31
Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board Member Dancann Pharma A/S appointed Louise Bertelsen Forman as a new additional board member. Reported Earnings • May 14
Full year 2022 earnings: Revenues miss analyst expectations Full year 2022 results: Revenue: kr.7.19m (up kr.6.32m from FY 2021). Net loss: kr.16.1m (loss widened 37% from FY 2021). Revenue missed analyst estimates by 4.9%. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Duyuru • Jan 04
DanCann Pharma A/S Appoints Peter Søndergaard as CFO DanCann Pharma A/S announces that the Company has appointed Peter Søndergaard as new Chief Financial Officer ('CFO'). Peter Søndergaard, who holds a Master of Science in Strategy and Management, has more than 15 years of experience from C-level employment in production and sales companies. At DanCann Pharma, Peter Søndergaard will lead the finance function in the growing organization, which consists of DanCann Pharma A/S and the subsidiary CannGros ApS. He will be responsible for developing and implementing relevant financial management tools adapted to the individual business areas in collaboration with the executive management team, of which he will be a part together with CEO Jeppe Krog Rasmussen, COO Sarah Mai Holm and CEO in the subsidiary CannGros, Louise Conradsen. Peter Søndergaard has joined the Company from the beginning of January together with two more new colleagues. DanCann Pharma has 18 employees from January 2023. Breakeven Date Change • Nov 16
No longer forecast to breakeven The analyst covering Dancann Pharma no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr.1.00m in 2024. New forecast suggests the company will make a loss of kr.9.00m in 2024. Breakeven Date Change • Nov 10
No longer forecast to breakeven The analyst covering Dancann Pharma no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr.1.00m in 2024. New forecast suggests the company will make a loss of kr.9.00m in 2024. Reported Earnings • Nov 06
Third quarter 2022 earnings released Third quarter 2022 results: Net loss: kr.10.5m (loss widened 287% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Pharmaceuticals industry in Sweden. Reported Earnings • Sep 02
Second quarter 2022 earnings released Second quarter 2022 results: Net loss: kr.4.64m (loss widened 161% from 2Q 2021). Over the next year, revenue is forecast to grow 522%, compared to a 90% growth forecast for the Pharmaceuticals industry in Sweden. Breakeven Date Change • Jun 10
Forecast to breakeven in 2024 The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Christian Carlsen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jun 04
Forecast to breakeven in 2025 The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests the company will make a profit of kr.1.00m in 2025. Average annual earnings growth of 13% is required to achieve expected profit on schedule. Duyuru • Mar 21
Dancann Pharma A/S Announces Executive Changes DanCann Pharma A/S announced that Magnus Østergaard Dahlmann has chosen to transfer the position of Chairman of the Board of Directors of the biopharmaceutical company DanCann Pharma A/S to Carsten Trads due to health reasons. Magnus Østergaard Dahlmann will continue as a member of the company's Board of Directors. The change of chairmanship is quite undramatic and is due to a desire from Magnus Østergaard Dahlmann to disengage resources in connection with a long-term course of treatment, and subsequently the Board of Directors has chosen to distribute the tasks differently. Duyuru • Mar 10
Dancann Pharma A/S Appoints Jens Markussen as Head of Production DanCann Pharma A/S announced the employment of Jens Markussen. Jens Markussen has been appointed as Head of Production at DanCann Pharma A/S. Jens Markussen joins the DanCann Pharma production team as the company's Head of Production. Jens Markussen will oversee all production and post-harvest activities of the BIOTECH PHARM1. This includes standardization of operations, compliance, applications, and approvals related to products produced at DanCann Pharma's BIOTECH PHARM1. Jens Markussen has already a proven track record within the medical cannabis industry as he is former Head of Production at Spectrum Therapeutics Denmark A/S, part of the Canopy Growth Corp. group. During his time at Spectrum Therapeutics Denmark, Jens has overseen the construction and approval of a 2,500 m2 GMP-facility for harvesting, drying, and packaging of dried cannabis. Before his time at Spectrum Therapeutics Denmark, Jens worked as Production Manager at Fertin Pharma A/S. In addition, Jens has proven track record in process and LEAN optimization within the pharma- and medical cannabis industry. Duyuru • Feb 26
DanCann Pharma A/S Signs a Letter of Intent with Canadian Tetra Bio-Pharma Inc. for the Exclusive Distribution of ReduvoT Adversa[® DanCann Pharma A/S announced the signing of a Letter of Intent with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines ReduvoT Adversa[®] and QixleefT in Denmark, Norway, Sweden, Finland, and Germany. Pursuant to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for the products, ReduvoT Adversa® and QixleefT. In addition, the agreement covers Tetra's OTC product EnjoucaT. ReduvoT Adversa® (dronabinol using a novel mucoadhesive-tablet route of administration) are indicated for the treatment of CINV patients (Chemotherapy-Induced Nausea and Vomiting) and for AIDS-related anorexia associated with weight loss. QixleefT and EnjoucaT are indicated for the treatment of uncontrolled pain in advanced cancer patients as well as for breakthrough pain. ReduvoT Adversa® technology will allow DanCann to launch a largely improved dronabinol version in the Nordic countries & Germany. The clinical benefits are numerous including: illimited first-pass metabolism leading to an improved bioavailability and consequently to reduced gastro-intestinal exposure and side-effects. The dosage regimen is likely to become BID as opposed to QID. This new technology signifies important intellectual property. QixleefT is a botanical cannabinoid-derived medicine, planned to become the first prescription product to be dispensed through pharmacies and prescribed by healthcare professionals. QIXLEEFT is inhaled through a Health Canada approved class 2 medical device. It is well characterized and will benefit from data protection, once approved by the EMA. The indications for this product are expected to be for advanced cancer pain and breakthrough pain. Lastly, ENJOUCAT is a medical cannabis therapeutic option (a non -registered) which will help European patients to manage their pain. Duyuru • Dec 18
Dancann Pharma A/S Submits New Application to the Danish Medicine Agency for Authorization to Produce Cannabis Intermediate Products Dancann Pharma A/S announced that it has submitted a new Application to the Danish Medicine Agency (DMA) for approval for authorization to produce cannabis intermediate products. Import, production and export of cannabis primary products and production of cannabis intermediate products are all activities appearing on the authorization to produce cannabis intermediate products.